SCHEMBL12853006

SCHEMBL12853006

Cc1ccc2c(c1)c1cc(-c3ccc4c(c3)c3ccccc3n4-c3ccc(-c4c5ccccc5c(-c5ccccc5)c5ccccc45)cc3)ccc1n2-c1ccc(C(F)(F)F)cc1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PPARG P37231 3/20 0.39
KIF11 P52732 3/20 0.39
PPARA Q07869 2/20 0.39
MGAM O43451 1/20 0.39
GAA P10253 1/20 0.39
SI P14410 1/20 0.39
MGAM2 Q2M2H8 1/20 0.39
KDM4E B2RXH2 1/20 0.38
ATM Q13315 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
TEAD1 P28347 1/20 0.37
TEAD4 Q15561 1/20 0.37
TEAD2 Q15562 1/20 0.37
TEAD3 Q99594 1/20 0.37
PIK3CA P42336 1/20 0.36
TACR1 P25103 3/20 0.36
TOP1 P11387 1/20 0.35
ESR1 P03372 1/20 0.35
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10108541 0.97 KIF11 (0.39) PPARGKIF11PPARAMGAMGAA
SCHEMBL10108736 0.96 KIF11 (0.40) PPARGKIF11PPARAMGAMGAA
SCHEMBL10108552 0.94 KIF11 (0.39) PPARGKIF11PPARAMGAMGAA
SCHEMBL14092849 0.93 KIF11 (0.39) PPARGKIF11PPARAMGAMGAA
SCHEMBL10108767 0.93 DHODH (0.39) PPARGKIF11PPARAMGAMGAA
SCHEMBL262448 0.93 KIF11 (0.44) PPARGKIF11PPARAMGAMGAA
SCHEMBL262532 0.93 KIF11 (0.44) PPARGKIF11PPARAMGAMGAA
SCHEMBL12461095 0.92 KIF11 (0.46) PPARGKIF11PPARAMGAMGAA
SCHEMBL12461793 0.92 KIF11 (0.46) PPARGKIF11PPARAMGAMGAA
SCHEMBL13432973 0.92 KIF11 (0.46) PPARGKIF11PPARAMGAMGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9136479-B2 Organic compound, anthracene derivative, and light-emitting element, light-emitting device, and electronic device using the anthracene derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2015-09-15 US disclosed
US-20150004731-A1 ORGANIC COMPOUND, ANTHRACENE DERIVATIVE, AND LIGHT-EMITTING ELEMENT, LIGHT-EMITTING DEVICE, AND ELECTRONIC DEVICE USING THE ANTHRACENE DERIVATIVE SEMICONDUCTOR ENERGY LAB (JP) 2015-01-01 US disclosed
US-8816098-B2 Organic compound, anthracene derivative, and light-emitting element, light-emitting device, and electronic device using the anthracene derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2014-08-26 US disclosed
US-8530672-B2 Organic compound, anthracene derivative, and light-emitting element, light-emitting device, and electronic device using anthracene derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2013-09-10 US disclosed
US-20120309984-A1 ORGANIC COMPOUND, ANTHRACENE DERIVATIVE, AND LIGHT-EMITTING ELEMENT, LIGHT-EMITTING DEVICE, AND ELECTRONIC DEVICE USING ANTHRACENE DERIVATIVE SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-12-06 US disclosed
US-8278655-B2 Organic compound, anthracene derivative, and light-emitting element, light-emitting device, and electronic device using anthracene derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309984-A1 ORGANIC COMPOUND, ANTHRACENE DERIVATIVE, AND LIGHT-EMITTING ELEMENT, LIGHT-EMITTING DEVICE, AND ELECTRONIC DEVICE USING ANTHRACENE DERIVATIVE CYP1A1, XPO7, AMY1A PPARG 1293/4885KIF11 4217/4885PPARA 2260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.